Literature DB >> 11000131

Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages.

M R Horton1, M A Olman, C Bao, K E White, A M Choi, B Y Chin, P W Noble, C J Lowenstein.   

Abstract

Pulmonary inflammation and fibrosis are characterized by increased turnover and production of the extracellular matrix as well as an impairment of lung fibrinolytic activity. Although fragments of the extracellular matrix component hyaluronan induce macrophage production of inflammatory mediators, the effect of hyaluronan on the fibrinolytic mediators plasminogen activator inhibitor (PAI)-1 and urokinase-type plasminogen activator (uPA) is unknown. This study demonstrates that hyaluronan fragments augment steady-state mRNA, protein, and inhibitory activity of PAI-1 as well as diminish the baseline levels of uPA mRNA and inhibit uPA activity in an alveolar macrophage cell line. Hyaluronan fragments alter macrophage expression of PAI-1 and uPA at the level of gene transcription. Similarly, hyaluronan fragments augment PAI-1 and diminish uPA mRNA levels in freshly isolated inflammatory alveolar macrophages from bleomycin-treated rats. These data suggest that hyaluronan fragments influence alveolar macrophage expression of PAI-1 and uPA and may be a mechanism for regulating fibrinolytic activity during lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000131     DOI: 10.1152/ajplung.2000.279.4.L707

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  25 in total

Review 1.  Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal.

Authors:  Jonathan D Powell; Maureen R Horton
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Fragments of extracellular matrix as mediators of inflammation.

Authors:  Tracy L Adair-Kirk; Robert M Senior
Journal:  Int J Biochem Cell Biol       Date:  2007-12-24       Impact factor: 5.085

Review 3.  Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells.

Authors:  Paul L Bollyky; Ben A Falk; Rebecca P Wu; Jane H Buckner; Thomas N Wight; Gerald T Nepom
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

Review 4.  Hyaluronan fragments as mediators of inflammation in allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2014-12-31       Impact factor: 3.144

Review 5.  Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology.

Authors:  Frances E Lennon; Patrick A Singleton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

6.  Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor.

Authors:  Samuel L Collins; Katharine E Black; Yee Chan-Li; Young-Hoon Ahn; Philip A Cole; Jonathan D Powell; Maureen R Horton
Journal:  Am J Respir Cell Mol Biol       Date:  2011-01-21       Impact factor: 6.914

Review 7.  The role of hyaluronan in the pathobiology and treatment of respiratory disease.

Authors:  Stavros Garantziotis; Martin Brezina; Paolo Castelnuovo; Lorenzo Drago
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

8.  The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion.

Authors:  Kara A Scheibner; Sada Boodoo; Samuel Collins; Katharine E Black; Yee Chan-Li; Paul Zarek; Jonathan D Powell; Maureen R Horton
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-14       Impact factor: 6.914

9.  Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON.

Authors:  Dahis Manzanares; Maria-Elena Monzon; Rashmin C Savani; Matthias Salathe
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-29       Impact factor: 6.914

Review 10.  The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance.

Authors:  Eleni Papakonstantinou; George Karakiulakis
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.